Reading the tape
NASDAQ: AKAN
Akanda Corp.
Healthcare · Drug Manufacturers - Specialty & Generic
Market Cap
$1.58M
52w High
$209.23
52w Low
$2.30
P/E
-0.76
Volume
15.80M
Outstanding Shares
32.37K
Price vs Fundamentals
Why The Stock Is Moving
Likely fundamental deteriorationModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -38.65%Revenue (TTM): -70.99%FCF (TTM): 44.34%
What changed
The stock fell 38.65% over the last year. Revenue declined 70.99% over the trailing twelve months. Operating margin moved from -531.05% to -978.82%. Free cash flow grew 44.34% over the trailing twelve months.
What the market seems to be pricing
The market appears to be responding to weaker operating momentum rather than only rerating the stock.
What would invalidate this read
Operating margin stands at -978.82%. Revenue declined 70.99% — this read reverses if that trend stabilizes. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Company profile
Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products in the United Kingdom, Lesotho, and internationally.
CEOKatharyn Field
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees46
IPO dateMar 15, 2022
Valuation
Forward P/E—
EV/EBITDA0.62
Enterprise value-$1.89M
Stock splits
Apr 13, 2026↓ Reverse
Every 9 shares became 2
Jan 12, 2026↓ Reverse
Every 5 shares became 1
Aug 26, 2025↓ Reverse
Every 25 shares became 8
Nov 14, 2024↓ Reverse
Every 2 shares became 1
May 23, 2024↓ Reverse
Every 40 shares became 1
Mar 9, 2023↓ Reverse
Every 10 shares became 1
Profitability & growth
Revenue growth-100%
Gross margin73.34%▲382.72%vs FY2023
Operating margin-978.82%▼12.57%vs FY2023
ROE-95.78%▼111.36%vs FY2023
Analyst consensus
Rating—
Target price—
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Apr 29, 2026
Q4 FY25 · EPS est — · Revenue est —
View